Wilson Sonsini Goodrich & Rosati and Goodwin advised MiroBio on the deal.MiroBio, a leader in the development of checkpoint agonists to treat autoimmune diseases, announced the…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
